BioNTech SE (ETR:22UA)
Germany
· Delayed Price · Currency is EUR 86.05
-1.05 (-1.21%)
Last updated: May 28, 2025
BioNTech SE Revenue
BioNTech SE had revenue of 182.80M EUR in the quarter ending March 31, 2025, a decrease of -2.56%. This brings the company's revenue in the last twelve months to 2.75B, up 0.61% year-over-year. In the year 2024, BioNTech SE had annual revenue of 2.75B, down -27.96%.
Revenue (ttm)
2.75B
Revenue Growth
+0.61%
P/S Ratio
7.56
Revenue / Employee
405.54K
Employees
6,772
Market Cap
20.76B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 2.75B | -1.07B | -27.96% |
| Dec 31, 2023 | 3.82B | -13.49B | -77.94% |
| Dec 31, 2022 | 17.31B | -1.67B | -8.78% |
| Dec 31, 2021 | 18.98B | 18.49B | 3,834.63% |
| Dec 31, 2020 | 482.30M | 373.70M | 344.11% |
| Dec 31, 2019 | Pro | Pro | Pro |
| Dec 31, 2018 | Pro | Pro | Pro |
| Dec 31, 2017 | Pro | Pro | Pro |
| Dec 31, 2016 | Pro | Pro | Pro |
| Dec 31, 2015 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Siemens Healthineers AG | 23.14B |
| Merck KGaA | 21.32B |
| Fresenius SE & Co. KGaA | 22.13B |
| Bayer Aktiengesellschaft | 46.58B |
| Fresenius Medical Care AG | 19.49B |
| Sartorius Aktiengesellschaft | 3.44B |
| Carl Zeiss Meditec AG | 2.17B |
| Fielmann Group AG | 2.33B |
BioNTech SE News
- 7 days ago - BioNTech to invest $1.3B in the U.K. to boost R&D efforts - Seeking Alpha
- 8 days ago - The FDA Is Limiting Covid Shots. But Moderna, Vaccine Stocks Jumped. - Investor's Business Daily
- 8 days ago - BioNTech plans up to $1.33 billion investment in the United Kingdom - Reuters
- 10 days ago - Novavax Wins Limited FDA Nod For COVID Shot—Cleared Only For Seniors, High-Risk Groups Amid Safety Scrutiny - Benzinga
- 13 days ago - CureVac Receives Additional Positive Validity Decision from European Patent Office in Ongoing Litigation Against BioNTech SE - Wallstreet:Online
- 13 days ago - BioNTech says bispecific antibody BNT324 is competitive against Summit's ivonescimab - Seeking Alpha
- 22 days ago - Why BioNTech Stock Got Trounced on Tuesday - The Motley Fool
- 22 days ago - SA analyst downgrades: COP, ON, BNTX, SKX, ALIZY, SFM - Seeking Alpha